Evidence mapPaperPMID 37446262Full record

ReviewInternational journal of molecular sciences2023

From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery-An Australian Example.

Payaal Kumar, Shintu Mathew, Rashmi Gamage, Frances Bodkin, Kerrie Doyle, Ilaria Rossetti, Ingrid Wagnon, Xian Zhou, Ritesh Raju, Erika Gyengesi and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Modulatory Effects ofAntioxidants (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Payaal KumarPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Shintu MathewPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Rashmi GamagePharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Frances BodkinPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Kerrie DoyleIndigenous Health Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Ilaria RossettiPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Ingrid WagnonPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.ORCID 0000-0001-8130-1531
Xian ZhouNICM Health Research Institute, Western Sydney University, Westmead, NSW 2145, Australia.
Ritesh RajuPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.ORCID 0000-0002-8163-9732
Erika GyengesiPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.ORCID 0000-0001-7371-7385
Gerald MünchPharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Camden and Campbelltown Hospitals · AUWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Australian rainforest is a rich source of medicinal plants that have evolved in the face of dramatic environmental challenges over a million years due to its prolonged geographical isolation from other continents. The rainforest consists of an inherent richness of plant secondary metabolites that are the most intense in the rainforest. The search for more potent and more bioavailable compounds from other plant sources is ongoing, and our short review will outline the pathways from the discovery of bioactive plants to the structural identification of active compounds, testing for potency, and then neuroprotection in a triculture system, and finally, the validation in an appropriate neuro-inflammatory mouse model, using some examples from our current research. We will focus on neuroinflammation as a potential treatment target for neurodegenerative diseases including multiple sclerosis (MS), Parkinson's (PD), and Alzheimer's disease (AD) for these plant-derived, anti-inflammatory molecules and highlight cytokine suppressive anti-inflammatory drugs (CSAIDs) as a better alternative to conventional nonsteroidal anti-inflammatory drugs (NSAIDs) to treat neuroinflammatory disorders.

Indexed as

Neurodegenerative DiseasesNeuroprotective AgentsAnimalsAnti-Inflammatory Agents, Non-SteroidalAustraliaBrainMiceAnti-Inflammatory Agents, Non-SteroidalNeuroprotective AgentsAlzheimer’s diseaseanti-inflammatory drugsdrug discoverymetabolitesneuroinflammationpre-clinical drug discovery

Identifiers

PMID37446262
PMCPMC10342267
OpenAlexW4383227337

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.